|
1
|
European Association for Study of Liver.
EASL clinical practice guidelines: Management of hepatitis C virus
infection. J Hepatol. 60:392–420. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang Y, Rao H, Chi X, Li B, Liu H, Wu L,
Zhang H, Liu S, Zhou G, Li N, et al: Detection of residual HCV-RNA
in patients who have achieved sustained virological response is
associated with persistent histological abnormality. EBioMedicine.
46:227–235. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Liaskou E, Wilson DV and Oo YH: Innate
immune cells in liver inflammation. Mediators Inflamm.
2012(949157)2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Pellicoro A, Ramachandran P, Iredale JP
and Fallowfield JA: Liver fibrosis and repair: Immune regulation of
wound healing in a solid organ. Nat Rev Immunol. 14:181–194.
2014.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Pinzani M: Pathophysiology of liver
fibrosis. Dig Dis. 33:492–497. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Wallace K, Burt AD and Wright MC: Liver
fibrosis. Biochem J. 411:1–18. 2008.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wynn TA and Barron L: Macrophages: Master
regulators of inflammation and fibrosis. Semin Liver Dis.
30:245–257. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Saha B, Kodys K and Szabo G: Hepatitis C
virus-induced monocyte differentiation into polarized M2
macrophages promotes stellate cell activation via TGF-β. Cell Mol
Gastroenterol Hepatol. 2:302–316.e8. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Murthy S, Larson-Casey JL, Ryan AJ, He C,
Kobzik L and Carter AB: Alternative activation of macrophages and
pulmonary fibrosis are modulated by scavenger receptor, macrophage
receptor with collagenous structure. FASEB J. 29:3527–3536.
2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Waidmann O, Brunner F, Herrmann E, Zeuzem
S, Piiper A and Kronenberger B: Macrophage activation is a
prognostic parameter for variceal bleeding and overall survival in
patients with liver cirrhosis. J Hepatol. 58:956–961.
2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Liu C, Tao Q, Sun M, Wu JZ, Yang W, Jian
P, Peng J, Hu Y, Liu C and Liu P: Kupffer cells are associated with
apoptosis, inflammation and fibrotic effects in hepatic fibrosis in
rats. Lab Invest. 90:1805–1816. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Grønbaek H, Sandahl TD, Mortensen C,
Vilstrup H, Møller HJ and Møller S: Soluble CD163, a marker of
Kupffer cell activation, is related to portal hypertension in
patients with liver cirrhosis. Aliment Pharmacol Ther. 36:173–180.
2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Bedossa P and Poynard T: An algorithm for
the grading of activity in chronic hepatitis C: The METAVIR
Cooperative Study Group. Hepatology. 24:289–293. 1996.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wai CT, Greenson JK, Fontana RJ,
Kalbfleisch JD, Marrero JA, Conjeevaram HS and Lok AS: A simple
noninvasive index can predict both significant fibrosis and
cirrhosis in patients with chronic hepatitis C. Hepatology.
38:518–526. 2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Sterling RK, Lissen E, Clumeck N, Sola R,
Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT,
Thomas DL, et al: Development of a simple noninvasive index to
predict significant fibrosis in patients with HIV/HCV coinfection.
Hepatology. 43:1317–1325. 2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Iwata Y, Enomoto H, Sakai Y, Aizawa N,
Tanaka H, Ikeda N, Takashima T, Ishii A, Hasegawa K, Yuri Y, et al:
Elevation of the AST to ALT ratio in association with the severity
of esophageal varices in patients with HCV-related compensated
liver cirrhosis. Hepatogastroenterology. 60:149–152.
2013.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Wan J, Benkdane M, Teixeira-Clerc F,
Bonnafous S, Louvet A, Lafdil F, Pecker F, Tran A, Gual P, Mallat
A, et al: M2 Kupffer cells promote M1 Kupffer cell apoptosis: A
protective mechanism against alcoholic and nonalcoholic fatty liver
disease. Hepatology. 59:130–142. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z,
Zhao JM, Zhang B, Shi M, Ding X, et al: Circulating and liver
resident CD4+CD25+ regulatory T cells actively influence the
antiviral immune response and disease progression in patients with
hepatitis B. J Immunol. 177:739–747. 2006.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ziegler-Heitbrock L: The CD14+ CD16+ blood
monocytes: Their role in infection and inflammation. J Leukoc Biol.
81:584–592. 2007.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Beljaars L, Schippers M, Reker-Smit C,
Martinez FO, Helming L, Poelstra K and Melgert BN: Hepatic
localization of macrophage phenotypes during fibrogenesis and
resolution of fibrosis in mice and humans. Front Immunol.
5(430)2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kuniholm MH, Hanna DB, Landay AL, Kaplan
RC and Ley K: Soluble CD163 is associated with noninvasive measures
of liver fibrosis in hepatitis C virus- and hepatitis C virus/human
immunodeficiency virus-infected women. Hepatology. 61:734–735.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Lidofsky A, Holmes JA, Feeney ER, Kruger
AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE,
et al: Macrophage activation marker soluble CD163 is a dynamic
marker of liver fibrogenesis in human immunodeficiency
virus/hepatitis C virus coinfection. J Infect Dis. 218:1394–1403.
2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Lidofsky A, Holmes JA, Feeney ER, Kruger
AJ, Salloum S, Zheng H, Seguin IS, Altinbas A, Masia R, Corey KE,
et al: Macrophage Activation Marker Soluble CD163 Is a Dynamic
Marker of Liver Fibrogenesis in Human Immunodeficiency
Virus/Hepatitis C Virus Coinfection. J Infect Dis. 218:1394–1403.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lee J, French B, Morgan T and French SW:
The liver is populated by a broad spectrum of markers for
macrophages. In alcoholic hepatitis the macrophages are M1 and M2.
Exp Mol Pathol. 96:118–125. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Melino M, Gadd VL, Walker GV, Skoien R,
Barrie HD, Jothimani D, Horsfall L, Jones A, Sweet MJ, Thomas GP,
et al: Macrophage secretory products induce an inflammatory
phenotype in hepatocytes. World J Gastroenterol. 18:1732–1744.
2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kazankov K, Barrera F, Møller HJ, Bibby
BM, Vilstrup H, George J and Grønbaek H: Soluble CD163, a
macrophage activation marker, is independently associated with
fibrosis in patients with chronic viral hepatitis B and C.
Hepatology. 60:521–530. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Hiraoka A, Horiike N, Akbar SM, Michitaka
K, Matsuyama T and Onji M: Soluble CD163 in patients with liver
diseases: Very high levels of soluble CD163 in patients with
fulminant hepatic failure. J Gastroenterol. 40:52–56.
2005.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Holland-Fischer P, Grønbæk H, Sandahl TD,
Moestrup SK, Riggio O, Ridola L, Aagaard NK, Møller HJ and Vilstrup
H: Kupffer cells are activated in cirrhotic portal hypertension and
not normalised by TIPS. Gut. 60:1389–1393. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Aroucha DC, do Carmo RF, Moura P, Silva
JL, Vasconcelos LR, Cavalcanti MS, Muniz MT, Aroucha ML, Siqueira
ER, Cahú GG, et al: High tumor necrosis factor-α/interleukin-10
ratio is associated with hepatocellular carcinoma in patients with
chronic hepatitis C. Cytokine. 62:421–425. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Nelson DR, Lauwers GY, Lau JY and Davis
GL: Interleukin 10 treatment reduces fibrosis in patients with
chronic hepatitis C: A pilot trial of interferon nonresponders.
Gastroenterology. 118:655–660. 2000.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Thompson K, Maltby J, Fallowfield J,
McAulay M, Millward-Sadler H and Sheron N: Interleukin-10
expression and function in experimental murine liver inflammation
and fibrosis. Hepatology. 28:1597–1606. 1998.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Van Thiel DH, Gavaler JS, Wright H and
Tzakis A: Liver biopsy. Its safety and complications as seen at a
liver transplant center. Transplantation. 55:1087–1090.
1993.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Castera L: Noninvasive methods to assess
liver disease in patients with hepatitis B or C. Gastroenterology.
142:1293–1302.e4. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Adams LA: Biomarkers of liver fibrosis. J
Gastroenterol Hepatol. 26:802–809. 2011.PubMed/NCBI View Article : Google Scholar
|
